Athena Athena

X
[{"orgOrder":0,"company":"Cedilla Therapeutics","sponsor":"Casdin Capital","pharmaFlowCategory":"D","amount":"$57.6 million","upfrontCash":"Undisclosed","newsHeadline":"Cedilla Therapeutics Announces $57.6 Million Series B Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery"},{"orgOrder":0,"company":"Cedilla Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","amount":"$82.6 million","upfrontCash":"Undisclosed","newsHeadline":"Cedilla Therapeutics Completes $82.6M Series B Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"October 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Cedilla Therapeutics","sponsor":"Bayer AG","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bayer to Acquire Exclusive License from Cedilla Therapeutics on Selective Inhibitors in Pre-Clinical Precision Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"}]

Find Clinical Drug Pipeline Developments & Deals by Cedilla Therapeutics

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            The collaboration strengthens Bayer’s early pipeline in precision oncology by gaining rights to develop and commercialize Cedilla’s CyclinE1/CDK2 complex inhibitors which selectively address oncogenic drivers.

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Bayer AG

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement June 01, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Proceeds from the financing will support Cedilla’s continued growth and development of its two lead programs, an inhibitor of TEAD for the treatment of solid tumors, and a highly selective inhibitor of CDK2/Cyclin E for the treatment of multiple tumors.

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: RA Capital Management

            Deal Size: $82.6 million Upfront Cash: Undisclosed

            Deal Type: Series B Financing October 25, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Proceeds from this financing will support ongoing efforts to build a broad portfolio of small molecule medicines, including the identification and preclinical development of Cedilla’s first two product candidates.

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Small molecule

            Partner/Sponsor/Collaborator: Casdin Capital

            Deal Size: $57.6 million Upfront Cash: Undisclosed

            Deal Type: Series B Financing October 13, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY